Bernstein initiates coverage of U.S. small- and mid-cap biopharma, with Nuvalent as the top pick

Overview

This report is Bernstein's initiation coverage of the U.S. small- and mid-cap biopharma sector. The core view is that biotech investing is not simply a bet on pipeline stories, but should distinguish winners from losers based on drug-development logic, clinical data quality, probability of success in registrational Phase 3 trials, competitive landscape, and DCF valuation. The report names Nuvalent as the top pick, arguing that its ALK+ NSCLC drug neladalkib and ROS1+ NSCLC drug zidesamtinib have potential best-in-class characteristics and that the market has not fully priced in their commercial opportunity.

Core views

The report's bull-bear split is clear: bullish on Nuvalent and Neurocrine, bearish on Summit, and neutral but cautious on BioNTech, Revolution Medicines, Jazz and Incyte. Nuvalent's investment case comes from strong clinical data, a high probability of success and an underappreciated target-patient penetration rate; Neurocrine benefits from Crenessity's first-mover advantage in CAH and Ingrezza's long lifecycle. By contrast, Summit is heavily dependent on ivonescimab and lacks current revenue and diversified late-stage assets; the report believes its PD-1/VEGF strategy faces a high risk of failing to deliver statistically significant survival benefit.

Analysis framework

The report takes a drug-developer's perspective on equity research, combining event forecasting, external scenario analysis of registrational clinical trials, Probability of Technical Success, cross-trial comparisons, market penetration assumptions, and DCF valuation. For Nuvalent, the analysis focuses on the current standards of care for ALK/ROS1-targeted therapy, unmet need, patient testing and treatment rates, resistance mutations, CNS efficacy, mDOR/ORR and other clinical endpoints, as well as the durability of response and safety potential of the new drugs relative to competitors.

Methodology notes

• 估值DCF valuation

  discounted cash flow valuation

  The report assigns target prices based on DCF for each company and combines risk-adjusted peak revenue, pipeline success probabilities, and the competitive landscape to assess upside or downside.

• 临床开发Probability of Technical Success

  probability of technical success

  The report uses industry-standard PTS to assess the probability that registrational trials will succeed, for example osavampator, direclidine, RASolute-303, and Ziihera-related trials.

• 事件研究Event forecasting

  clinical event forecasting

  The report forecasts stock catalysts and risks around events such as ASCO presentations, Phase 3 readouts, FDA approvals, first-patient enrollment, and potential approval timelines.

• 临床证据比较Cross-trial comparison

  cross-trial comparison

  The report repeatedly compares neladalkib with competitors such as Lorlatinib and Alectinib on metrics including ORR, mDOR, CNS response and PFS, but this method inherently has limitations due to differences in patient baseline characteristics and trial design.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• NUVL.US

  core long; report top pick

  Strengths

  neladalkib and zidesamtinib target ALK+ NSCLC and ROS1+ NSCLC, respectively, with potential best-in-class efficacy, CNS activity, and coverage of resistance mutations; risk-adjusted peak revenue forecasts are above consensus.

  Weaknesses

  The company is still in the clinical stage, and commercialization as well as key Phase 3 validation have not yet fully materialized; some judgments rely on cross-trial comparisons and immature data.

  Comparison

  neladalkib is compared with Lorlatinib, Alectinib and other ALK TKIs, while zidesamtinib's penetration logic is benchmarked against the mature EGFRm NSCLC market established by Tagrisso.

  Risks

  ALKAZAR and other Phase 3 trials may miss expectations, mDOR or CNS efficacy may not hold up as the data mature, ROS1 penetration may improve more slowly than expected, and competitive pressure may intensify.

• NBIX.US

  positive coverage

  Strengths

  Crenessity has roughly a four-year first-mover advantage in CAH, Ingrezza and Crenessity both have long LOE runways, and early osavampator data are encouraging.

  Weaknesses

  Over the long term, new pipeline assets are still needed to fill the revenue gap after Crenessity and Ingrezza lose exclusivity.

  Comparison

  Crenessity faces potential atumelnant competition; Ingrezza competes with Austedo in the TD and Huntington's disease chorea markets.

  Risks

  Crenessity penetration could miss expectations, osavampator or direclidine could fail in Phase 3, and competing drugs could erode market opportunity earlier than expected.

• SMMT.US

  core short or avoid

  Strengths

  ivonescimab has market attention, and upcoming ASCO and HARMONi program events could act as catalysts.

  Weaknesses

  The company has no marketed drug, no revenue, and a highly concentrated late-stage asset base; it is effectively a single bet on ivonescimab.

  Comparison

  Like BNTX, it follows a PD-1/VEGF or PD-L1/VEGF-related development logic, but SMMT lacks BNTX's cash, revenue, and diversified-pipeline buffer.

  Risks

  If the HARMONi readout is materially better than the report expects, the bearish view could reverse quickly; regulatory approval could also create a short-term counter-catalyst.

• BNTX.US

  neutral but cautious

  Strengths

  COVID vaccine revenue, a diversified pipeline, and BMS cash provide funding for higher-PTS drug development.

  Weaknesses

  Programs such as pumitamig in PD-L1/VEGF are viewed as aggressive, and the report thinks consensus is too optimistic about PTS and market share.

  Comparison

  Compared with SMMT, BNTX faces the same PD-L1/VEGF clinical-validation risk but has a stronger financial and pipeline buffer.

  Risks

  PD-L1/VEGF registrational trial failures, risk-adjusted peak sales below market expectations, and declining COVID revenue.

• RVMD.US

  neutral but limited upside

  Strengths

  Daraxonrasib is viewed as a potential winner in pancreatic cancer, and the report believes RASolute-303 is likely to be positive.

  Weaknesses

  The current share price already reflects a substantial amount of future portfolio revenue upside, leaving limited room for further appreciation.

  Comparison

  Core revenue is highly concentrated in pancreatic cancer; the report says 84% of risk-adjusted revenue comes from this area.

  Risks

  RASolute-303 may be negative or weaker than expected; the report estimates roughly a 25% chance of a negative trial outcome.

• JAZZ.US

  neutral but cautious

  Strengths

  Ziihera could become the company's first major oncology driver and has the potential to offset part of the decline in neuroscience revenue.

  Weaknesses

  Xywav and Epidiolex face near-term competition risk, and the revenue replacement potential from Ziihera is highly uncertain.

  Comparison

  Ziihera faces competition from Enhertu, especially where marketing and trial-design disadvantages exist in GEA and breast-cancer sequencing settings.

  Risks

  EmpowHER-BC-303 may fail, Enhertu competition may be stronger than expected, and neuroscience core-drug revenue may decline faster than Ziihera scales.

• INCY.US

  neutral but growth path is unclear

  Strengths

  Monjuvi and other lifecycle-management efforts offer some contribution, and INCA033989 could become a future growth catalyst.

  Weaknesses

  Jakafi lacks a clear path to reaccelerating revenue growth after its 2028 LOE, and Jakafi accounts for 60% of FY25 revenue.

  Comparison

  Compared with biotech companies that have more explicit clinical or commercialization catalysts, INCY's near-term growth narrative is weaker.

  Risks

  Jakafi revenue declines, LCM efforts may not be enough to fill the gap, and INCA033989's trial design or clinical results may disappoint.

Key data

• NUVL rating and target priceOutperform, $189, +85%Based on DCF valuation, Nuvalent is the top pick.
• Nuvalent risk-adjusted peak portfolio revenue$9.4BThe report says this forecast is 49% above consensus.
• Current targeted-therapy rate among newly diagnosed ROS1+ NSCLC patients~37%The report believes this treatment rate is materially lower than the 85% benchmark established by Tagrisso in the mature EGFRm NSCLC market, showing room for penetration gains for zidesamtinib.
• Neladalkib ORR in patients previously treated with a 2G ALK TKI and Lorlatinib-naive46%Cross-trial comparison versus about 40% in a comparable Lorlatinib cohort.
• Neladalkib first-line TKI-naive cohort response rate86%Among 44 evaluable patients, 91% remained in response at 12 months, but the data are still maturing.
• Neladalkib ORR in patients with the G1202R mutation83%The report says this is above the roughly 58% cross-trial comparison result for Lorlatinib.
• NBIX rating and target priceOutperform, $221, +43%Core drivers are Crenessity, Ingrezza, and osavampator potential.
• Crenessity peak revenue forecast$2.4BThe report says this is 57% above consensus, supported by the CAH first-mover advantage and early launch performance.
• SMMT rating and target priceUnderperform, $7.70, -57%The report believes key Phase 3 endpoints related to ivonescimab face a high risk of failure.
• BioNTech cash and balance sheet€16.8B by end of 1Q26The report believes BNTX faces PD-L1/VEGF risk but is buffered by COVID vaccine revenue, a diversified pipeline, and BMS cash.

Impact & implications

For the portfolio, the report supports a more stringent clinical-evidence tiering of U.S. small- and mid-cap biotech: prioritize companies with strong data, high trial success probabilities, still-underappreciated market penetration, and valuations that do not fully reflect peak revenue; avoid companies that depend heavily on a single high-risk mechanism, lack revenue support, or whose share prices already fully discount optimistic clinical outcomes. Nuvalent is positioned as a core long with substantial upside, while Summit is positioned as a high-risk downside name.

Risks

• Nuvalent's key clinical data still need to mature, and cross-trial comparisons may be affected by differences in patient baseline characteristics, endpoint definitions, and trial design.
• If ALKAZAR and other registrational Phase 3 trials do not meet expectations, the investment case for neladalkib becoming the new standard of care would be directly weakened.
• Penetration of targeted therapy in ROS1+ NSCLC may improve more slowly than assumed in the report, leaving zidesamtinib's market opportunity below expectations.
• If Summit- and BioNTech-related PD-1/VEGF or PD-L1/VEGF trials show clear OS benefit, the report's cautious or bearish view could be disproven.
• Neurocrine, Jazz, and Incyte all face revenue replacement risk from LOE, competitor entry, or failed pipeline readouts.
• Biotech valuation is highly sensitive to clinical events, regulatory decisions, financing conditions, and risk appetite.

What to watch

• Nuvalent neladalkib ALKAZAR Phase 3 enrollment progress, mPFS readout, and mature CNS efficacy data.
• Nuvalent zidesamtinib first key approval in ROS1+ NSCLC, real-world adoption rate, and pace of market penetration.
• Summit HARMONi-6 mid-year OS results at ASCO 2026, as well as the later key endpoints for HARMONi-3, HARMONi-7, and HARMONi-GI3.
• Neurocrine Crenessity early launch market-share changes, and osavampator and direclidine Phase 3 topline readouts.
• BioNTech pumitamig, gotistobart and ADC pipeline clinical progress, and cash-use efficiency.
• RVMD RASolute-303 first-line pancreatic cancer Phase 3 results.
• Jazz Ziihera clinical and commercial progress in BTC, GEA and breast cancer, plus the competitive landscape versus Enhertu.
• Incyte Jakafi revenue decline after LOE, Monjuvi contribution, and INCA033989 registrational trial design.